Government
Privately-held Swedish pharmaceutical company Lobsor Pharmaceuticals AB is eying the U.S. market for a potential treatment for neurodegenerative diseases such as Parkinson’s disease.
One year after spinning out from AstraZeneca’s MedImmune, Viela Bio is already anticipating filing a Biologics License Application with the U.S. Food and Drug Administration for its lead asset, inebilizumab.
The FY19 Defense Appropriation provides $100 million to the Department of Defense Prostate Cancer Research Program to support innovative, high-impact prostate cancer research.
Wolters Kluwer, Health now equips astronauts at the National Aeronautics and Space Administration on board the International Space Station with the most current medical information and access to expert-authored recommendations.
In a Phase III trial, a higher proportion of deaths was observed in the venetoclax arm compared to the control arm of the trial.
The FY19 Defense Appropriations Act provides $15 million to the Department of Defense Neurofibromatosis Research Program to support innovative, high-impact NF research.
Department of Defense Parkinson’s Research Program Funding Opportunities for Fiscal Year 2019 (FY19)
The FY19 Defense Appropriation provides $16 million to the Department of Defense Parkinson’ Research Program to support research to understand, prevent, diagnose, and treat Parkinson’s disease.
The life sciences industry is incredibly important to the financial ecosystem of the Golden State. Last year the industry generated total annual revenue of $177.1 billion in the state.
Allergan, which has been a leader in the migraine space, hopes to have a new treatment available for patients using a new mechanism of action for acute treatment of migraine.
It’s a busy week for the U.S. Food and Drug Administration (FDA) with quite a number of pending drug approvals, several of which were delayed for a variety of reasons. Here’s a look.
PRESS RELEASES